RPG Life Sciences Limited (RPGLIFE) — Announcement | 13 July 2026

StockFin.ai

Try Free

📢 Key Event
RPG Life Sciences partners with Archerchem for Naprosyn ES launch

💡 Investor Takeaway
The partnership expands RPG Life Sciences' chronic therapy portfolio with a differentiated product targeting a specific patient segment.

RPG Life Sciences announced a partnership with Archerchem Healthcare to launch Naprosyn ES, a combination NSAID drug for pain management with gastro-protection, targeting unmet needs in elderly and gastro-sensitive patients across India.

📄 View Original Announcement (PDF)

📊 Stock Analysis — RPGLIFE ✨ Ask AI About This

About RPG Life Sciences Limited (RPGLIFE)

Healthcare · Pharmaceuticals & Biotechnology · Listed on NSE

Market Cap: ₹3,791.57 Cr P/E: 32.9

View full RPGLIFE stock details →

📡 Get AI alerts when RPGLIFE files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track RPGLIFE — Free

💡 Ask AI about this filing

"How will Naprosyn ES pricing compare to existing NSAIDs?" "What is RPG Life Sciences' revenue contribution from chronic therapies?" "How does Archerchem's supply capacity support pan-India distribution?"

Ask AI Free →

📊 More RPGLIFE filings

See all RPGLIFE filings →

🔥 Also filed on 13 July 2026

RAMASTEEL Rama Steel Tubes Limited Announcement ANDHRAPAP ANDHRA PAPER LIMITED Corporate Action JUBLINGREA Jubilant Ingrevia Limited Financial Results POCL Pondy Oxides & Chemicals Limited Corporate Action MIRZAINT Mirza International Limited Insider Trading CAPITALSFB Capital Small Finance Bank Limited Financial Results

View all today's announcements →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

📡 Get AI alerts when RPGLIFE files new disclosures

Track RPGLIFE filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track RPGLIFE — Free

Free account · 2 AI queries/day